Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Mease
Lamont E. Mease, Omaha, NE US
| Patent application number | Description | Published |
|---|---|---|
| 20080268112 | Ground Meat and Meat Analog Compositions Having Improved Nutritional Properties - The invention provides ground meat and meat analog compositions having reduced fat and cholesterol. The ground meat compositions comprise a structured plant protein product and optionally meat. | 10-30-2008 |
Phillip Mease, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20090028794 | Uses and compositions for treatment of psoriatic arthritis - The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject. | 01-29-2009 |
Phillip J. Mease, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20080311043 | Uses and compositions for treatment of psoriatic arthritis - The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject. | 12-18-2008 |
Ronnie C. Mease, Fairfax, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20110064657 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), BIOLOGICAL EVALUATION, AND USE AS IMAGING AGENTS - The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors. | 03-17-2011 |
Ronnie Charles Mease, Fairfax, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20110142760 | PSMA-BINDING AGENTS AND USES THEREOF - Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. | 06-16-2011 |